FindTrial
Sign In

The guiding role of circulating tumor cell detection technology on TACE treatment and guiding prognosis in hepatocellular carcinoma after radical excision

The guiding role of circulating tumor cell detection technology on TACE treatment in hepatocellular carcinoma after radical excision with microvascular invasion

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-16010183
Enrollment
Unknown
Registered
2016-12-18
Start date
2016-12-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Interventions

TACE treatment group:TACE
Control:without TACE

Sponsors

Shandong Provincial Qianfoshan Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: According to the clinical diagnostic standard of primary liver cancer diagnosis standard, patients with radical resection combined with postoperative pathology confirmed hepatocellular carcinoma at the same time, an important function of heart and lung and other organs can be tolerated treatment, the patients with complete clinical and pathological data, no other special anticancer therapy, no other history of cancer.

Exclusion criteria

Exclusion criteria: Pathology confirmed that patients with non hepatocellular carcinoma; severe heart, liver, lung, brain, kidney and other organ complications; due to various reasons lost.

Design outcomes

Primary

MeasureTime frame
disease free survival;—

Countries

China

Contacts

Public ContactLi Jie

Shandong Provincial Qianfoshan Hospital

lijie0503@126.com+86 13791120825

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 17, 2026